Absci Corp (ABSI) Stock Price, Quote & News

Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 360 949 1041

Website: www.absci.com

Address:

18105 SE Mill Plain Boulevard, Vancouver, United States

Mindegap Feb. 24 at 8:57 PM

$CRBU, $PRME, $MXCT, $ABSI Finally.

1 · Reply

TT_ Feb. 20 at 6:53 PM

$ABSI when are we going to see an accountant or update. This thing is draining

0 · Reply

Y007 Feb. 20 at 3:09 PM

$ABSI come on back down so I can load up

0 · Reply

Momabeat Feb. 20 at 2:47 PM

$ABSI bought a few here!

0 · Reply

flam70 Feb. 19 at 4:18 AM

$ABSI https://www.forbes.com/sites/tiriasresearch/2026/02/18/drug-discovery-gets-a-boost-with-ai/

0 · Reply

BioHunter1 Feb. 18 at 6:31 PM

$ABSI 0.9% average total Institutional reduction in January and first part of February. Insiders sold minor amounts as well. The selling is over and it’s time for a rebound.

0 · Reply

BioHunter1 Feb. 18 at 5:33 PM

$ABSI back in at $2.58. It would be real nice to see $2.90+ today if not $3

1 · Reply

RiskWalker Feb. 18 at 9:21 AM

$ABSI Synthetic biology platform where partnerships validate long-term promise.

0 · Reply

SteveJohnsonis Feb. 17 at 10:33 PM

$ABSI $LLY $NVDA $RXRX

0 · Reply

sogenerous Feb. 17 at 5:32 PM

$LLY $RXRX $ABSI feels like its a goner - maybe once it goes to 1s another squeeze short term before 0 . hemorrhaging money and old CEO left . All thats left is for $NVDA to sell their stake and its a slow bleed to 0 while they loot the coffers

7 · Reply

Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

Feb 17, 2026, 8:00 AM EST - 7 days ago

Absci to Participate in Upcoming Investor Conferences

Jan 14, 2026, 10:16 PM EST - 5 weeks ago

Absci Corporation (ABSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Dec 16, 2025, 8:00 AM EST - 2 months ago

Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:52 PM EST - 2 months ago

Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript

Dec 11, 2025, 8:00 AM EST - 2 months ago

Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization

Dec 10, 2025, 8:00 AM EST - 2 months ago

Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research

Dec 4, 2025, 8:00 AM EST - 2 months ago

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia

Nov 21, 2025, 7:23 PM EST - 3 months ago

Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 12, 2025, 10:31 PM EST - 3 months ago

Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 3 months ago

Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

Oct 29, 2025, 4:05 PM EDT - 4 months ago

Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

Oct 15, 2025, 8:00 AM EDT - 4 months ago

Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial

Sep 11, 2025, 12:10 PM EDT - 5 months ago

Absci Boosts AI-Powered Drug Discovery With Oracle And AMD Collaboration

AMD ORCL

Sep 11, 2025, 8:00 AM EDT - 5 months ago

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

Sep 9, 2025, 12:13 AM EDT - 6 months ago

Absci Corporation (ABSI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 25, 2025, 4:05 PM EDT - 6 months ago

Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg

Aug 13, 2025, 12:25 AM EDT - 7 months ago

Absci Corporation (ABSI) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 7 months ago

Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results

Aug 7, 2025, 2:00 AM EDT - 7 months ago

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

Jul 30, 2025, 4:05 PM EDT - 7 months ago

Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

Jul 25, 2025, 8:34 AM EDT - 7 months ago

Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session

ASTS INTC

Jul 24, 2025, 8:45 PM EDT - 7 months ago

Absci Announces Pricing of Public Offering of Common Stock

Jul 24, 2025, 4:54 PM EDT - 7 months ago

Absci Announces Proposed Public Offering of Common Stock

Jul 7, 2025, 8:00 AM EDT - 8 months ago

Absci Appoints Biopharma Leader Mary Szela to Board of Directors

May 13, 2025, 10:45 PM EDT - 10 months ago

Absci Corporation (ABSI) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 10 months ago

Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

May 13, 2025, 4:01 PM EDT - 10 months ago

Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

Apr 14, 2025, 4:05 PM EDT - 11 months ago

Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

Apr 3, 2025, 3:15 PM EDT - 11 months ago

Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market

Mar 19, 2025, 8:15 AM EDT - 1 year ago

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

HQY TNXP

Mar 18, 2025, 7:37 PM EDT - 1 year ago

Absci Corporation (ABSI) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 1 year ago

Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

Mar 4, 2025, 4:05 PM EST - 1 year ago

Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

Mar 4, 2025, 4:00 PM EST - 1 year ago

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2025, 8:00 AM EST - 1 year ago

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum

Feb 18, 2025, 8:00 AM EST - 1 year ago

Absci to Participate in the TD Cowen 45th Annual Health Care Conference

Jan 22, 2025, 1:22 PM EST - 1 year ago

Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside

AMD

Jan 22, 2025, 8:00 AM EST - 1 year ago

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Jan 13, 2025, 2:05 AM EST - 1 year ago

Absci Looks Cheap And Positioned For Growth With AMD's AI Backing

AMD

Jan 10, 2025, 7:30 AM EST - 1 year ago

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

Jan 8, 2025, 7:00 AM EST - 1 year ago

Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

Jan 6, 2025, 8:00 AM EST - 1 year ago

Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health

Nov 12, 2024, 10:01 AM EST - 1 year ago

Absci Corporation (ABSI) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:30 AM EST - 1 year ago

Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results

Nov 7, 2024, 8:00 AM EST - 1 year ago

Absci to Host R&D Day on December 12, 2024

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024

Oct 3, 2024, 12:36 PM EDT - 1 year ago

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Aug 16, 2024, 11:50 PM EDT - 1 year ago

Absci Corporation (ABSI) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results

Mindegap Feb. 24 at 8:57 PM

$CRBU, $PRME, $MXCT, $ABSI Finally.

1 · Reply

TT_ Feb. 20 at 6:53 PM

$ABSI when are we going to see an accountant or update. This thing is draining

0 · Reply

Y007 Feb. 20 at 3:09 PM

$ABSI come on back down so I can load up

0 · Reply

Momabeat Feb. 20 at 2:47 PM

$ABSI bought a few here!

0 · Reply

flam70 Feb. 19 at 4:18 AM

$ABSI https://www.forbes.com/sites/tiriasresearch/2026/02/18/drug-discovery-gets-a-boost-with-ai/

0 · Reply

BioHunter1 Feb. 18 at 6:31 PM

$ABSI 0.9% average total Institutional reduction in January and first part of February. Insiders sold minor amounts as well. The selling is over and it’s time for a rebound.

0 · Reply

BioHunter1 Feb. 18 at 5:33 PM

$ABSI back in at $2.58. It would be real nice to see $2.90+ today if not $3

1 · Reply

RiskWalker Feb. 18 at 9:21 AM

$ABSI Synthetic biology platform where partnerships validate long-term promise.

0 · Reply

SteveJohnsonis Feb. 17 at 10:33 PM

$ABSI $LLY $NVDA $RXRX

0 · Reply

sogenerous Feb. 17 at 5:32 PM

7 · Reply

Cade1968 Feb. 17 at 3:49 PM

$ABSI - apparently AMD have announced in their 13F that they’ve purchased 10m shares in here , surprised it didn’t pump this ?

1 · Reply

JennyRowes Feb. 14 at 7:43 PM

$ABSI or $RXRX - any reason to think we might get good news at earnings??

1 · Reply

BillionerOfKing Feb. 13 at 6:17 PM

$ABSI Current Stock Price: $2.63 Contracts to trade: $3.0 ABSI Feb 20 2026 Call Entry: $0.05 Exit: $0.09 ROI: 94% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

aoab Feb. 13 at 4:27 PM

$ABSI what’s the real deal with this one? I think I like rxrx better

2 · Reply

Zmbz Feb. 13 at 3:42 PM

$ABSI heavy selling @2.80 someone trying to get out

0 · Reply

BioHunter1 Feb. 12 at 9:03 PM

$ABSI 257K+ buy at $2.42…

0 · Reply

BioHunter1 Feb. 12 at 7:13 PM

$ABSI $ABSI added too soon thinking 2.54 would be it. Now I think If it goes below $2.37 then 2.00 is next or even lower is possible.

0 · Reply

BioHunter1 Feb. 12 at 6:00 PM

$ABSI

0 · Reply

LabPsycho Feb. 12 at 2:55 PM

$ABSI I am not at all surprised its down (again). See below - like I was saying......

1 · Reply

BioHunter1 Feb. 12 at 2:41 PM

$ABSI While all other stocks are flying, biotechs are left behind in the dust. The shorts found their feeding grounds

0 · Reply

N0_Brainers Feb. 12 at 1:15 AM

$ABSI one + news and shorts are in big problem here.. no liquidity and they are holding their positions.

1 · Reply

Maksiuland Feb. 11 at 7:12 PM

$ABSI https://www.youtube.com/watch?v=BukJeQM9Mn8

0 · Reply

Market Cap	398.49M
Revenue (ttm)	4.53M
Net Income (ttm)	-103.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,276.16%
Debt to Equity Ratio	0.01

Volume	2,130,300
Avg Vol	3,359,644
Day's Range	N/A - N/A
Shares Out	150.37M
Stochastic %K	79%
Beta	2.11
Analysts	Strong Sell
Price Target	$8.04